VTRS Viatris
- Official Name: VIATRIS INC.
- Headquarters: 1000 Mylan Boulevard, CANONSBURG, PA, 15317 US
- CEO: Scott Smith
- Website: viatris.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Won by 0.114 | (1.148) - (1.262) | ||
| 2025-07-17 | 1 | Lost by 0.035 | 3.539 - 3.574 | ||
| 2025-07-23 | 1R | Won by 0.041 | 1.375 - 1.334 | ||
| 2025-07-24 | 2 | Lost by 3.762 | 1.848 - 5.610 | ||
| 2025-07-29 | 2R | Lost by 7.392 | (1.790) - 5.602 | ||
| 2025-07-31 | 3 | Lost by 11.733 | (7.735) - 3.998 | ||
| 2025-08-06 | 2R | Lost by 1.695 | (2.228) - (0.533) | ||
| 2025-08-07 | 4 | Won by 11.440 | 8.268 - (3.172) | ||
| 2025-08-07 | 1R | Won by 4.827 | 6.554 - 1.727 | ||
| 2025-08-14 | 5 | Won by 17.683 TOTW | 13.980 - (3.703) | ||
| 2025-08-21 | 6 | Won by 0.012 | 1.044 - 1.032 | ||
| 2025-08-21 | 2R | Won by 0.742 | 0.435 - (0.307) | ||
| 2025-08-28 | 7 | Won by 0.629 | (2.701) - (3.330) | ||
| 2025-09-04 | 8 | Won by 0.182 | (0.752) - (0.934) | ||
| 2025-09-04 | 3R | Lost by 3.349 | (2.092) - 1.257 | ||
| 2025-09-11 | 9 | Lost by 2.434 | (1.547) - 0.887 | ||
| 2025-09-18 | 10 | Won by 1.323 | (3.084) - (4.407) | ||
| 2025-09-25 | 11 | Won by 2.440 | (3.162) - (5.602) | ||
| 2025-10-02 | 12 | Won by 7.262 TOTW | 6.391 - (0.871) | ||
| 2025-10-09 | 13 | Lost by 6.316 | (1.195) - 5.121 | ||
| 2025-10-16 | 14 | Won by 0.182 | 1.094 - 0.912 | ||
| 2025-10-23 | 15 | Won by 1.715 | 2.396 - 0.681 |
Latest News
Yahoo - 2026-10-16
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phe...
Yahoo - 2026-10-16
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.
Benzinga - 2026-10-16
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phe...
Yahoo - 2026-10-16
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults...
SeekingAlpha - 2026-10-16
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimerâs revenue growth, and key risk/reward driversâread now. Cli...
ChartMill - 2026-10-14
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Show more
SeekingAlpha - 2026-10-12
Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade)
Yahoo - 2026-10-12
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
SeekingAlpha - 2026-10-12
Viatris: Improved Confidence Drives M&A Action Again
Yahoo - 2026-10-09
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Benzinga - 2026-10-09
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Yahoo - 2026-10-09
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Benzinga - 2026-10-09
How Your Taxes Will Be Different Next Year, And Why You'll Have Trump To Thank
SeekingAlpha - 2026-10-09
Viatris To Acquire Pacira BioSciences: What Investors Should Know
SeekingAlpha - 2026-10-09
Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years
Yahoo - 2026-10-09
Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
Yahoo - 2026-10-08
Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
Yahoo - 2026-10-08
Sector Update: Healthcare Stocks Softer Late Afternoon
Yahoo - 2026-10-08
Viatris to acquire Pacira BioSciences for $1.65 billion
Yahoo - 2026-10-08
Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?
Yahoo - 2026-10-08
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Yahoo - 2026-10-08
Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
Yahoo - 2026-10-08
Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout
Yahoo - 2026-10-08
Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal
Yahoo - 2026-10-08
Viatris boosts pain drug portfolio with $1.7B buyout of Pacira
Yahoo - 2026-10-08
Why Pacira BioSciences Skyrocketed Today
Yahoo - 2026-10-08
2 Stocks Drawing Bearish Options Activity Today
Yahoo - 2026-10-08
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
Yahoo - 2026-10-08
Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion
Benzinga - 2026-10-08
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
ChartMill - 2026-10-08
These S&P500 stocks that are showing activity before the opening bell on Thursday.
Yahoo - 2026-10-08
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Yahoo - 2026-10-06
VTRS vs. AVTR: Which Stock Is the Better Value Option?
Yahoo - 2026-10-06
Should Value Investors Buy Viatris (VTRS) Stock?
Benzinga - 2026-10-05
UBS Maintains Buy on Viatris, Raises Price Target to $26
Yahoo - 2026-10-05
FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application
Yahoo - 2026-10-05
Harrow Closes Acquisition of TYRVAYA®
SeekingAlpha - 2026-09-30
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success
Yahoo - 2026-09-29
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
ChartMill - 2026-09-28
Stay informed with the top movers within the S&P500 index on Monday.
Yahoo - 2026-09-25
Viatris sues Novo Nordisk over generic Wegovy patent dispute
Yahoo - 2026-09-24
Is Viatris Stock Outperforming the S&P 500?
Benzinga - 2026-09-23
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25
Benzinga - 2026-09-23
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields
Yahoo - 2026-09-20
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
Yahoo - 2026-09-19
3 US Stocks That Could Gain If Buyers Shift Away From India
Yahoo - 2026-09-16
Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
Benzinga - 2026-09-16
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13
Benzinga - 2026-09-16
Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy
Yahoo - 2026-09-14
3 Healthcare Stocks That Fall Short
SeekingAlpha - 2026-09-09
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive
Benzinga - 2026-09-09
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20
Benzinga - 2026-09-08
Argus Research Maintains Buy on Viatris, Raises Price Target to $20
Yahoo - 2026-09-02
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
Yahoo - 2026-08-31
3 Cash-Producing Stocks That Concern Us
Yahoo - 2026-08-29
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
SeekingAlpha - 2026-08-28
17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years
Yahoo - 2026-08-28
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Yahoo - 2026-08-27
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
Yahoo - 2026-08-25
The Real Engine That Could Power Tesla Stock Higher
Yahoo - 2026-08-25
Dell Stock's Massive Guidance Raise Has A Catch
Yahoo - 2026-08-19
Viatris' China Policy Concerns Overstated, UBS Says
Yahoo - 2026-08-19
3 S&P 500 Stocks We Keep Off Our Radar
Yahoo - 2026-08-18
3 Stocks Under $50 We’re Skeptical Of
Yahoo - 2026-08-15
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call
Yahoo - 2026-08-13
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
Yahoo - 2026-08-13
Viatris (VTRS) Q2 2026 Earnings Call Transcript
SeekingAlpha - 2026-08-12
Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio: Q2 2026 Update
Yahoo - 2026-08-12
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Yahoo - 2026-08-11
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Yahoo - 2026-08-11
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
Yahoo - 2026-08-09
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
Yahoo - 2026-08-09
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval
Yahoo - 2026-08-09
Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress
Yahoo - 2026-08-06
Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...
SeekingAlpha - 2026-08-06
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Yahoo - 2026-08-06
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
Benzinga - 2026-08-06
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
SeekingAlpha - 2026-08-06
Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation
Yahoo - 2026-08-06
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Yahoo - 2026-08-06
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Yahoo - 2026-08-06
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
Yahoo - 2026-08-06
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Yahoo - 2026-08-06
Viatris Reports Second-Quarter 2026 Financial Results
Benzinga - 2026-08-06
Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate
Benzinga - 2026-08-06
Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to $14.550B-$14.950B vs $14.783B Est
SeekingAlpha - 2026-08-05
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Yahoo - 2026-08-05
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Yahoo - 2026-08-05
CVS Health (CVS) Q2 Earnings and Revenues Beat Estimates
Yahoo - 2026-08-04
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
Yahoo - 2026-08-04
Is Wall Street Bullish or Bearish on Viatris Stock?
Yahoo - 2026-08-04
Viatris Announces Quarterly Dividend
Yahoo - 2026-08-03
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates
SeekingAlpha - 2026-08-03
Viatris: A Reasonable Valuation
Yahoo - 2026-08-02
Viatris (VTRS) Wins FDA Approval For Gwyn Lo Contraceptive Patch
SeekingAlpha - 2026-07-31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Yahoo - 2026-07-30
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
Yahoo - 2026-07-29
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
SeekingAlpha - 2026-07-29
18 Ideal 'Safer' Buyable July Dogs Emerge After 10 Years Of Digging
Yahoo - 2026-07-28
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
Yahoo - 2026-07-24
3 Healthcare Stocks We Keep Off Our Radar
Benzinga - 2026-07-24
Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease
Yahoo - 2026-07-22
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
Yahoo - 2026-07-22
Viatris’ Quarterly Earnings Preview: What You Need to Know
CNBC - 2026-07-22
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Yahoo - 2026-07-20
3 Unpopular Stocks We’re Skeptical Of
Yahoo - 2026-07-17
Financial Stocks Rally To New Highs. JPMorgan Is One Of Them.
SeekingAlpha - 2026-07-14
Organon & Co: Great Odds, Small Prize, Big Penalty
Benzinga - 2026-07-14
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Yahoo - 2026-07-09
VTRS or DHR: Which Is the Better Value Stock Right Now?
Yahoo - 2026-07-09
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
Yahoo - 2026-07-07
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
Yahoo - 2026-07-06
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?
Yahoo - 2026-07-05
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results
Yahoo - 2026-07-05
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now
Yahoo - 2026-07-02
Viatris (VTRS) is a Great Momentum Stock: Should You Buy?
Yahoo - 2026-06-30
Theravance Stock Down 3% After Zymeworks Announces Buyout
Yahoo - 2026-06-29
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Benzinga - 2026-06-29
Viatris’ VR‑205 Phase 3 Trial in Japan Met Primary and Key Secondary Endpoints; Safety Profile Aligned With Global Studies, NDA Filing Planned by End‑2026
Yahoo - 2026-06-23
VTRS vs. DHR: Which Stock Is the Better Value Option?
Yahoo - 2026-06-23
Are Investors Undervaluing Viatris (VTRS) Right Now?
SeekingAlpha - 2026-06-23
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)
Yahoo - 2026-06-19
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?
Yahoo - 2026-06-18
FDA Seeks Updated Labeling for Testosterone Therapies
Yahoo - 2026-06-16
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds
Yahoo - 2026-06-16
Viatris Recognized as One of the 2026 Best Workplaces™ in Canada
Yahoo - 2026-06-14
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns
Yahoo - 2026-06-14
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story
Yahoo - 2026-06-11
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Yahoo - 2026-06-05
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Yahoo - 2026-06-03
How Is Zoetis’ Stock Performance Compared to Other Healthcare Stocks?
SeekingAlpha - 2026-05-28
90 Top Ten-Year Dog Collection Yields 22 Ideal Buys From 41 'Safer' Sorts In May
Yahoo - 2026-05-24
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam
Yahoo - 2026-05-23
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Yahoo - 2026-05-21
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?
Yahoo - 2026-05-19
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Yahoo - 2026-05-19
1 Stock Under $50 to Target This Week and 2 We Avoid
Yahoo - 2026-05-18
This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why?
Yahoo - 2026-05-18
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call
Yahoo - 2026-05-18
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
Benzinga - 2026-05-18
Viatris' New Drug Application For Moderate-To-Severe Acute Pain Treatment Receives FDA's Acceptance For Review
Yahoo - 2026-05-15
Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)?
Yahoo - 2026-05-13
3 Unprofitable Stocks That Fall Short
SeekingAlpha - 2026-05-13
Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain
SeekingAlpha - 2026-05-12
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Finnhub - 2026-05-12
Transcript : Viatris Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08
SeekingAlpha - 2026-05-12
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)
Yahoo - 2026-05-11
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance
SeekingAlpha - 2026-05-11
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
SeekingAlpha - 2026-05-08
Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2026 Update
Yahoo - 2026-05-08
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Benzinga - 2026-05-08
RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding
Benzinga - 2026-05-08
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $18
Benzinga - 2026-05-08
Truist Securities Maintains Buy on Viatris, Raises Price Target to $20
Benzinga - 2026-05-08
Valneva Announces HSR Clearance For Lyme Vaccine Collaboration With Pfizer
Benzinga - 2026-05-08
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Yahoo - 2026-05-07
Viatris Inc. Q1 2026 Earnings Call Summary
Yahoo - 2026-05-07
Assessing Viatris (VTRS) Valuation After Its Recent Share Price Rebound
Yahoo - 2026-05-07
Viatris (VTRS) Q1 2026 Earnings Transcript
Yahoo - 2026-05-07
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
ChartMill - 2026-05-07
These S&P500 stocks have an unusual volume in today's session
ChartMill - 2026-05-07
What's going on in today's session: S&P500 gap up and gap down stocks
SeekingAlpha - 2026-05-07
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Yahoo - 2026-05-07
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
Yahoo - 2026-05-07
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates
ChartMill - 2026-05-07
Viatris (NASDAQ:VTRS) Shares Rise as Q1 Earnings Top Estimates
Yahoo - 2026-05-07
Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue
Yahoo - 2026-05-07
Viatris Reports First-Quarter 2026 Financial Results
Finnhub - 2026-05-07
Transcript : Viatris Inc., Q1 2026 Earnings Call, May 07, 2026
Finnhub - 2026-05-07
Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Finnhub - 2026-05-07
Viatris beats first-quarter estimates on China strength, branded drug sales
SeekingAlpha - 2026-05-07
Viatris Inc. 2026 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-05-07
Viatris Affirms FY2026 Adj EPS Guidance of $2.33-$2.47 vs $2.44 Est; Affirms FY2026 Sales Guidance of $14.450B-$14.950B vs $14.638B Est
Finnhub - 2026-05-07
Viatris : VTRS Q1 2026 Non-GAAP Reconciliations - FINAL
Finnhub - 2026-05-07
Viatris : VTRS Q1 2026 Earnings Presentation - FINAL
Finnhub - 2026-05-07
Viatris : VTRS Q1 2026 Earnings Infographic - FINAL
Finnhub - 2026-05-07
Viatris: Q1 Earnings Snapshot
Benzinga - 2026-05-07
Viatris Q1 Adj. EPS $0.59 Beats $0.50 Estimate, Sales $3.510B Beat $3.357B Estimate
Yahoo - 2026-05-06
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS
Yahoo - 2026-05-06
Are Wall Street Analysts Bullish on Viatris Stock?
Yahoo - 2026-05-05
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
Yahoo - 2026-05-05
Edwards names Theodora Mistras as CFO
Yahoo - 2026-05-04
Edwards Lifesciences Announces Appointment of CFO
Yahoo - 2026-05-04
Viatris Announces Chief Financial Officer Transition
Benzinga - 2026-05-04
Viatris Appoints Chief Accounting Officer Paul Campbell As Interim CFO, Effective May 8, Succeeding Theodora Mistras
Yahoo - 2026-05-03
Is It Too Late To Consider Viatris (VTRS) After Its Strong One Year Share Price Run
Yahoo - 2026-04-30
Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30?
Yahoo - 2026-04-30
Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
SeekingAlpha - 2026-04-29
24 Ideal 'Safer' April Buys Nabbed In 10 Years Of Dogcatcher Digging
Yahoo - 2026-04-23
Viatris' Q1 2026 Earnings: What to Expect
Yahoo - 2026-04-18
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
Yahoo - 2026-04-16